Company Research Report: Novartis AG

Company Overview

Name: Novartis AG
Mission: Reimagine medicine to improve and extend people's lives.
Vision: Become the most valued and trusted medicines company in the world.
Strategy: Deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

Founded: No information is available
Founder(s): No information is available

Key People:

Fiona H. Marshall, President, Biomedical Research

Shreeram Aradhye, President, Development and Chief Medical Officer

Headquarters: No information is available
Number of Employees: 78,000
Revenue: No information is available
Known For: Innovative medicines reaching more than 250 million people worldwide.

Products

Product List:

1. Adakveo® (crizanlizumab)

Therapeutic Area: Oncology

Availability: USA

2. Afinitor Disperz®/Votubia® (everolimus)

Therapeutic Area: Oncology

Availability: Multiple countries including USA, Germany, Australia

3. Afinitor®/Votubia® (everolimus)

Therapeutic Area: Oncology

Availability: Multiple countries including USA, Germany, Australia

4. Aimovig® (erenumab)

Therapeutic Area: Neuroscience

Availability: USA, Russia

5. Arzerra® (ofatumumab)

Therapeutic Area: Oncology

Availability: Multiple countries including USA, Germany, Australia

6. Azarga®/Azorga® (brinzolamide, timolol)

Therapeutic Area: Ophthalmology

Availability: Germany, Australia

7. Beovu® (brolucizumab)

Therapeutic Area: Ophthalmology

Availability: USA, Russia

Description & Key Features:

No high-level descriptions or key features for the individual products are available.

Recent Developments

Latest News and Milestones:

1. Leqvio®

Date: August 28, 2024

Development: Demonstrated clinically meaningful LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk.

2. Fabhalta® (iptacopan)

Date: August 8, 2024

Development: Received FDA accelerated approval for the reduction of proteinuria in primary IgA nephropathy (IgAN).

3. Novartis Financial Results – Q2 2024

Date: July 18, 2024

Update: Continued strong sales growth and core margin expansion; raised FY 2024 bottom-line guidance.

4. Scemblix®

Date: July 29, 2024

Development: Granted FDA Priority Review for the treatment of adults with newly diagnosed CML.

New Partnerships:

1. Borealis Biosciences

Date: August 22, 2024

Development: Established through a creative deal structure involving the divestment of the legacy Chinook site.

New Features Added to Existing Products:

No information is available.

Therapeutic Areas

Cardiovascular, Renal and Metabolic: Focus on innovative treatments and early interventions to manage cardiovascular diseases and chronic kidney diseases.

Immunology: Aim to enable people with immunological conditions to live without compromise.

Neuroscience: Committed to changing the course of disease progression in neurological conditions.

Oncology: Focus on developing therapies that restore hope to those battling cancer.

Technology Platforms

1. Chemistry: Discovery of low molecular weight synthetic molecules optimized as medicines.
2. Biotherapeutics: Medicines derived from the molecules of life for specific diseases.
3. xRNA: Utilizes forms of ribonucleic acids to treat illnesses.
4. Radioligand Therapy: Delivers precision-targeted radiation to cancer cells.
5. Gene and Cell Therapy: Modifies genetic makeup for genetic or inherited diseases and uses cells for therapy delivery.